Home
Search
Study Topics
Glossary
|
Study 12 of 628 for search of: | received on or after 12/30/2008 |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Medicis Pharmaceutical Corporation |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00823901 |
The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.
Condition | Intervention | Phase |
---|---|---|
Rosacea |
Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel Drug: placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks |
Estimated Enrollment: | 86 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Clindamycin/Tretinoin Gel: Experimental
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
|
Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
apply to the face at bed time
|
2: Placebo Comparator |
Drug: placebo
placebo gel - apply to face at bedtime
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Department of Dermatology - Stanford School of Medicine | |
Stanford, California, United States, 94305 | |
United States, Massachusetts | |
CURTIS - Massachussetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Alexa Kimball, MD, MPH | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( Alexandra B. Kimball, MD, MPH ) |
Study ID Numbers: | 2008-P-001828 |
Study First Received: | January 14, 2009 |
Last Updated: | January 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00823901 |
Health Authority: | United States: Food and Drug Administration |
rosacea clindamycin tretinoin clinical study treatment |
Rosacea Clindamycin Clindamycin-2-phosphate Skin Diseases Tretinoin |
Keratolytic Agents Anti-Infective Agents Anti-Bacterial Agents Protein Synthesis Inhibitors Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Dermatologic Agents Pharmacologic Actions |